课题基金 / 基金详情

Mechanisms of T-cell induced-APC cytotoxicity in lupus

Mechanisms of T-cell induced-APC cytotoxicity in lupus
狼疮中 T 细胞诱导的 APC 细胞毒性机制
批准号:
6924545
负责人:
Mariana J Kaplan
金额:
$12.85万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-20 至 2007-06-30

项目摘要

项目成果

Mariana J Kaplan的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):申请资金的具体目的是由主要研究者开发一个独立的研究项目。在过去的四年中,申请人一直在狼疮(SLE)的T细胞免疫学和发病机制领域进行基础科学研究。该提案是申请人目前对单核细胞/巨噬细胞(M θ)凋亡研究的延伸。假设:凋亡诱导分子介导CD4+狼疮T细胞引起的自体单核细胞/M θ杀伤。通过这种机制杀死靶细胞可导致自身抗体的产生。具体目的:探讨狼疮cd4 + T细胞诱导单核细胞/M θ凋亡的途径。申请人将通过阻断自身反应性CD4+ T细胞杀伤单核细胞/M θ的凋亡通路,测试是否有可能在SLE动物模型中抑制自身免疫的发展。巨噬细胞凋亡在触发或增强自身免疫中的作用也将被研究。方法:a)采用流式细胞术检测SLE和对照T细胞表面死亡受体配体的表达。b)通过细胞毒性实验,确定这些凋亡通路在SLE单核细胞/M θ中是否有功能,阻断这些分子是否可以抑制SLE T细胞对自体单核细胞/M θ的杀伤。c)考虑到涉及M θ细胞毒性的途径的冗余性,申请人将在体外测试,是否抑制死亡受体下游的死亡信号(FADD, caspases, FLIP)足以抑制这些配体诱导的单核细胞/M θ细胞凋亡。d)体内研究将试图表征单克隆抗体或融合蛋白阻断单核细胞/巨噬细胞死亡受体配体是否能抑制小鼠SLE的发展,以及是否能消除组织巨噬细胞;本身(体内含氯膦酸脂质体)足以在动物模型中诱导自身免疫。提出的研究结果可能确定SLE中自身抗原产生的潜在机制。这可能会导致治疗干预措施的发展,旨在扭转这些异常,消除或阻止这种疾病的发病和严重程度。主办方和机构承诺为申请人提供受保护的时间、职业发展和资源。
英文摘要
DESCRIPTION (provided by applicant): The application requests funding with the specific intent of developing an independent research program by the principal investigator. The applicant has been pursuing basic science research in the areas of T cell immunology and pathogenesis of lupus (SLE) for the past four years. The proposal is an extension of the applicant's current research on monocyte/macrophage (M theta) apoptosis. Hypothesis: Apoptosis-inducing molecules mediate the autologous monocyte/M theta killing caused by CD4+ lupus T cells. Target cell killing by this mechanism can lead to the generation of autoantibodies. Specific aims: To determine the pathways involved in monocyte/M theta apoptosis induced by lupusCD4+ T cells. The applicant will test whether it's possible to inhibit the development of autoimmunity in an SLE animal model, by blocking the apoptotic pathways involved in monocyte/M theta killing by autoreactive CD4+ T cells. The role of macrophage apoptosis in triggering or augmenting autoimmunity will also be investigated. Methods: a) Measurement of cell surface expression of death-receptor ligands on SLE and control T cells by flow cytometry. b) With cytotoxicity assays, determine whether these apoptotic pathways are functional in SLE monocytes/M theta and whether blocking these molecules can inhibit the autologous monocyte/M theta killing by SLE T cells. c) Given the redundancy of the pathways involved in M theta cytotoxicity, the applicant will test, in vitro, if inhibiting the death signals downstream of the death receptors (FADD, caspases, FLIP) is sufficient to inhibit monocyte/M theta apoptosis induced by these ligands. d) In vivo studies will try to characterize whether the blockade on monocyte/macrophage death-receptor ligands by monoclonal antibodies or fusion proteins, can inhibit the development of murine SLE, and whether the elimination of tissue macrophages; per se (with clodronate liposomes in vivo) is sufficient to induce autoimmunity in an animal model. The results of the studies proposed might identify potential mechanisms involved in the generation of autoantigens in SLE. These could lead into the development of therapeutic interventions designed to reverse these abnormalities and abrogate or block the onset and severity of this disease. The sponsor and the institution are committed to contributing protected time, career development and resources to the applicant.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Abnormal vascular repair in lupus: a link to premature atherosclerosis
Abnormal vascular repair in lupus: a link to premature atherosclerosis
Abnormal vascular repair in lupus: a link to premature atherosclerosis
PPAR-y agonists, RA and cardiovascular disease
海外基金